Summit Therapeutics Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Summit Therapeutics Inc. (SMMT) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$33.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-07-23
- Summit Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$33.00K.
- Summit Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$92.00K.
- Summit Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $43.00K, a 77.49% decline year-over-year.
- Summit Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was -$189.00K.
- Summit Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was -$255.00K, a 256.44% decline from fiscal 2024.
- Summit Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $163.00K.
- Summit Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was -$555.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$33.00K 10-Q · filed 2026-07-23 | -$125.00K derived: sum of 2 quarters · filed 2026-07-23 | ||
| 2026-03-31 | -$92.00K 10-Q · filed 2026-07-23 | |||
| 2025-12-31 | -$255.00K 10-K · filed 2026-02-23 | |||
| 2025-09-30 | $43.00K 10-Q · filed 2025-10-20 | -$146.00K derived: sum of 2 quarters · filed 2026-07-23 | -$424.00K derived: sum of 3 quarters · filed 2026-07-23 | -$401.00K derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | -$189.00K 10-Q · filed 2026-07-23 | -$467.00K derived: sum of 2 quarters · filed 2026-07-23 | -$444.00K derived: sum of 3 quarters · filed 2026-07-23 | -$253.00K derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | -$278.00K 10-Q · filed 2026-07-23 | -$255.00K derived: sum of 2 quarters · filed 2026-07-23 | -$64.00K derived: sum of 3 quarters · filed 2026-07-23 | -$114.00K derived: sum of 4 quarters · filed 2026-07-23 |
| 2024-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $214.00K derived: sum of 2 quarters · filed 2026-02-23 | $164.00K derived: sum of 3 quarters · filed 2026-02-23 | $163.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | $191.00K 10-Q · filed 2025-10-20 | $141.00K derived: sum of 2 quarters · filed 2025-10-20 | $140.00K 10-Q · filed 2024-10-30 | $15.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | -$50.00K 10-Q · filed 2025-10-20 | -$51.00K 10-Q · filed 2024-08-06 | -$176.00K derived: sum of 3 quarters · filed 2026-02-23 | -$62.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | -$1.00K 10-Q · filed 2025-10-20 | -$126.00K derived: sum of 2 quarters · filed 2026-02-23 | -$12.00K derived: sum of 3 quarters · filed 2026-02-23 | |
| 2023-12-31 | -$125.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$11.00K derived: sum of 2 quarters · filed 2026-02-23 | -$555.00K 10-K · filed 2026-02-23 | |
| 2023-09-30 | $114.00K 10-Q · filed 2024-10-30 | -$430.00K 10-Q · filed 2024-10-30 | ||
| 2023-03-31 | $497.00K 10-Q · filed 2024-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |